Hikma at a glance
Discover what drives us
Latest news
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results
22 February 2024
- Hikma launches Cisatracurium Besylate Injection, USP in the US Press Release, Product 25 March 2025 Hikma launches Cisatracurium Besylate Injection, USP in the US
- Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg Press Release, Product 20 March 2025 Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
- Developing our pipeline in growing therapeutic areas Story, Corporate 19 March 2025 Developing our pipeline in growing therapeutic areas
- Focusing on our quality manufacturing Story, Corporate 19 March 2025 Focusing on our quality manufacturing